EVELYN RAMOS: Open Payments
NPI 1033679006 · ADELPHI, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,174 in 45 payments from 9 companies in 2025. Trend: 2023 $30 · 2024 $508 · 2025 $1,174
Food & beverage: $1,075Education: $99
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 24 | $643 |
| Madrigal Pharmaceuticals | 8 | $209 |
| Ardelyx, Inc. | 3 | $93 |
| ABBVIE INC. | 2 | $55 |
| PFIZER INC. | 2 | $51 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| GENZYME CORPORATION | 1 | $25 |
| Novo Nordisk Inc | 1 | $22 |
Products named: TREMFYA, REZDIFFRA, IBSRELA, LINZESS, XELJANZ, XIFAXAN, DUPIXENT, Wegovy.
Industry payments across MD — which companies pay providers there.
